FDA advises healthcare professionals not to use ChloraPrep 3 mL applicators

March 22, 2021

The U.S. Food and Drug Administration (FDA) is advising healthcare professionals not to use ChloraPrep 3 mL applicators manufactured by Becton, Dickinson and Company (BD), due to microbial contamination risks. The drug was distributed globally and is labeled with “CareFusion, El Paso, TX.” 

BD’s investigation confirmed the product’s lid, when exposed to higher temperature and humidity, can fail and lead to microbial contamination which may cause serious infections, especially in patients with compromised immune systems. 

This drug is used to sanitize skin prior to surgery or catheter procedures. Healthcare professionals should use an available alternative. 

FDA recommended on March 15, 2021, that BD expand their recall (initiated in June 2020) to include all unexpired ChloraPrep 3 mL applicators in the U.S. The company’s limited recall, which covered countries and U.S. territories with tropical climates, was due to the lid defect after a finding of fungal growth that breached the product seal. To date, the company has not taken action to expand their recall and remove additional dangerous drugs from the U.S. market. 

FDA is not aware of any adverse events associated with use of BD’s ChloraPrep 3 mL applicators. FDA encourages healthcare professionals and patients to report adverse events or quality problems experienced with the use of any medication to FDA’s MedWatch Adverse Event Reporting program. 

FDA has the advisory.